Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Direct Extubation Versus Extubation After a Spontaneous Breathing Trial in Patients at Low Risk of Extubation Failure

NCT07019636 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-07-15
Last updated
2026-07-17

Condition(s) studied

Weaning From Mechanical Ventilation, Extubation

Investigational drug(s) / intervention(s)

Weaning strategy with direct extubation (no spontaneous breathing trial)Weaning strategy with extubation only after a successful spontaneous breathing

Weaning strategy with direct extubation (no spontaneous breathing trial): Patients will be extubated within the 60 minutes following randomization

Weaning strategy with extubation only after a successful spontaneous breathing: Patients will undergo a spontaneous breathing trial and will be extubated only in case of successful spontaneous breathing

Study summary

This randomized controlled open label trial aims at comparing a weaning strategy including a spontaneous breathing trial as a prerequisite for extubation to a weaning strategy without a spontaneous breathing trial (direct extubation) in patients with readiness to be weaned criteria and considered at low risk of extubation failure. The main endpoint will be the proportion of patients successfully extubated within the 24 hours after randomization as compared to extubation after a successful spontaneous breathing trial (SBT).

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age older than 18 years and \< 65 years old * Nasal or oral intubation longer than 24 hours and less than 4 days * Satisfaction to each following weaning readiness criteria: 1. Respiratory rate \< 35 cycles per minute 2. SpO2 \>90% with FiO2\<40% and PEEP\<8 cmH2O 3. RASS score between -2 and +2 with low level or no sedatives 4. No need or low doses of vasopressors 5. Adequate cough * Inform consent by patient or legal representative or the close relative or emergency inclusion procedure. Exclusion Criteria: * Risk factor for extubation failure as defined by any of the following criteria: * Chronic cardiac disease (left ejection fraction below 45%, documented history of cardiogenic pulmonary edema, permanent atrial fibrillation). * Chronic respiratory disease (severe COPD, documented restricted lung disease or obesity-hypoventilation syndrome) * Body mass index \> 30 kg/m2 * Airway patency problems, including high risk of developing laryngeal edema, inability to deal with respiratory secretions, brain injury, documented swallowing disorders * Tracheostomy * Underlying chronic neuromuscular disease * Do not resuscitate orders * Pregnant or lacting woman * Patient under guardianship * Patient without healthcare insurance * Refusal to participate and sign the written consent * Patients with traumatic brain injury * Post surgery patients * Patients included in another interventional trial that may have an impact on the evaluation criteria of the present study * Patient under AME

Primary outcome measure(s)

  • Proportion of patients extubated within the 24 hours after randomization and who will remain free from mechanical ventilation until 72 hours. — From Day 1 to Day 3
    The rate of patients extubated within the 24 hours after randomization and who will remain free from mechanical ventilation until 72 hours.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Pitié Salpêtrière Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07019636 on ClinicalTrials.gov ↗ ← All trials in France